E-mail Print PDF


cardiac_PETLantheus Medical Imaging, Inc., a global leading company providing medical imaging systems, announced that seven abstracts for studies discussing two of the company’s cardiac Positron Emission Tomography (PET) imaging agents are going to be highlighted at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC2010). The event will take place from the 23th to the 26th of September in Philadelphia. The abstracts are discussing the preliminary results of two currently conducted studies.

New PET Cardiac Imaging Agents.

The first one is a single site Phase 2 study on flurpiridaz F 18, also known as BMS747158, which is providing a new option as a myocardial perfusion PET imaging agent, still under development, which could be used in diagnosing coronary artery diseases. The preliminary findings of the study will be discussed in a presentation titled "Preliminary results of absolute quantification of rest and stress myocardial blood flow with flurpiridaz F 18 PET in normal and coronary artery disease patients in a single-center study.” The second study is a Phase 1 data on LMI 1195, which is an innovative cardiac neuronal PET imaging agent. Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging, Inc., commented, “Lantheus is pleased that seven abstracts will be presented at ASNC2010 highlighting important data on our cardiovascular imaging pipeline candidates.These data continue to support the potential of PET technology for the diagnosis and evaluation of coronary artery disease and heart failure. We believe that next generation medical imaging tools like flurpiridaz F 18 and LMI 1195 can ultimately provide physicians with improved non-invasive and cost-effective options to evaluate and help manage cardiovascular diseases."

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.